Robèrt, J. http://orcid.org/0009-0005-3598-4155
Tsatsaris, E. http://orcid.org/0009-0002-7630-3991
Berinder, K.
Bonelli, L.
Burman, P. http://orcid.org/0000-0002-4844-8336
Dahlqvist, P.
Höybye, C.
Olsson, D. S. http://orcid.org/0000-0002-9734-0786
Ragnarsson, O. http://orcid.org/0000-0003-0204-9492
Vouzouneraki, K.
Åkerman, A.-K.
Ekman, B. http://orcid.org/0000-0001-8732-7361
Edén Engström, B. http://orcid.org/0000-0003-4514-5193
Funding for this research was provided by:
Region Uppsala
Region Östergötland
Pfizer
Linköping University
Article History
Received: 26 April 2023
Accepted: 2 October 2023
First Online: 18 October 2023
Declarations
:
: Daniel S. Olsson has been a consultant for Sandoz, Ipsen and Pfizer; has received unrestricted grants from Sandoz and Pfizer; and is an employee at AstraZeneca as of 8th August 2021. The other authors have nothing to declare.
: This study and the data collection it entailed have been approved by the Regional Ethics Review Board, Uppsala, Sweden (No. 2017/475). The Swedish Pituitary Register is approved by the Ethics Review Board, Karolinska Institute, Stockholm, Sweden (No. 2003/515/03 and No. 2012/915-32). Patients in the SPR must be informed and given the option to opt out of the register at any time. This study was performed in accordance with the Declaration of Helsinki 1964 and its later amendments.
: No informed consent is required for registration in national quality registers.